Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
First biosimilar insulin to receive regulatory approval in the EU
INDIANAPOLIS and RIDGEFIELD, Conn., Sept. 10, 2014 /PRNewswire/ -- The European Commission (EC) granted marketing authorisation for Eli Lilly and Company LLY, -0.86% and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim alliance. It received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) on June 26, 2014.
http://www.marketwatch.com/story/eu...-marketing-authorisation-in-europe-2014-09-10
'Abasria'
🙄
INDIANAPOLIS and RIDGEFIELD, Conn., Sept. 10, 2014 /PRNewswire/ -- The European Commission (EC) granted marketing authorisation for Eli Lilly and Company LLY, -0.86% and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim alliance. It received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) on June 26, 2014.
http://www.marketwatch.com/story/eu...-marketing-authorisation-in-europe-2014-09-10
'Abasria'
🙄